How Much? How Frequent? How Long? A Clinical Guide to New Therapies in Myelodysplastic Syndromes
Author:
Open Access
- 4 December 2010
- journal article
- research article
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2010 (1) , 314-321
Abstract
Advances in the treatment of myelodysplastic syndromes (MDSs) over the last decade have given patients and their hematologists a multitude of treatment options. Therapeutic options now exist that reduce disease-related symptoms, improve quality of life, and alter the natural history of the disease. Three drugs are now specifically Food and Drug Administration-approved for treatment of MDS: (1) azacitidine, (2) decitabine, and (3) lenalidomide. Clinical results with each of these agents, plus results with immunosuppressive therapy, are reviewed to guide clinical decision making. Although each therapy has made a substantial impact in improving the care of patients with MDS, unfortunately MDS treatment in 2010 ultimately fails in most patients, but these therapies provide a foundation on which we can build to further improve outcomes.Keywords
This publication has 50 references indexed in Scilit:
- Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabineProceedings of the National Academy of Sciences, 2010
- Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase–dependent pathwayBlood, 2010
- Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progressionBlood, 2009
- A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomideProceedings of the National Academy of Sciences, 2009
- Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13Blood, 2009
- Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic SyndromesJournal of Clinical Oncology, 2008
- Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drugJournal of Clinical Investigation, 2008
- Identification of RPS14 as a 5q- syndrome gene by RNA interference screenNature, 2008
- Lenalidomide inhibits the malignant clone and up-regulates theSPARCgene mapping to the commonly deleted region in 5q− syndrome patientsProceedings of the National Academy of Sciences, 2007
- Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndromeCancer, 2007